Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

PP405 is not commercially available or legitimate in Europe. Users are discussing the lack of availability of this product.

A potential new hair loss treatment, HMI-115, and the possibility of discontinuing finasteride in favor of it. The conversation also includes discussion about other benefits of using finasteride.

Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.

The conversation discusses the differences between PG/Ethanol and KB solutions for RU58841 application, focusing on potential scalp irritation. KB solution is suggested for those allergic to PG, though both contain ethanol which can dry the scalp.

The user tried Minoxidil without success, and Finasteride worked but caused sexual side effects even at a very low dose. They are seeking alternative treatments for hair loss as they cannot tolerate anti-androgens and are also in therapy for mental health.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

A user (seblt) who has had side effects from finasteride, minoxidil and RU58841 but is now trying pyrilutamide as a last resort, with other users providing advice and support. They have already seen some baby hairs growing after 10-14 days of treatment and will provide updates in 1-2 weeks.

The conversation is about someone planning to start finasteride for hair loss and wanting to interpret pre-treatment blood panels to assess the risk of side effects like gynecomastia. They list various tests to measure hormone levels and other health indicators.

The user had a hair transplant with 4500 grafts and has been using minoxidil twice daily for over a year but stopped finasteride due to severe side effects. The transplant cost $3500 and improved their self-confidence, positively affecting their dating life.

The conversation discusses using finasteride, dutasteride, minoxidil, and RU58841, along with a 10,000 graft hair transplant, to prevent magpies from targeting bald men. The title humorously references an eight-year-old's survey on magpies swooping bald men.

Bimatoprost, latanoprost, and travoprost can aid hair regrowth but are costly and less effective than minoxidil. They work best when combined with minoxidil and finasteride.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

A 23-year-old male has been using finasteride and topical minoxidil for 14 months with slight improvement, but recent shedding led him to switch to a new minoxidil formulation without success. He is considering using topical RU58841 or dutasteride to better address scalp DHT, as his bloodwork shows high total testosterone and mid-range DHT levels.

User discusses topical liposomal finasteride for hair loss, hoping to avoid breast growth side effect. Conversation includes using minoxidil, fluridil, and dermarolling, and mentions minimal systemic absorption of liposomal finasteride.

Topical melatonin may help reduce hair loss and increase hair thickness in people with androgenetic alopecia (AGA), with some studies showing positive results. It can be mixed with minoxidil for application, and its effectiveness might be enhanced when used with micro-needling, but results may vary among individuals.

Scientists discover SCUBE3 molecule for potential baldness cure. Mice used in research for hair growth signaling.

RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

The hair transplant at Eugenix in New Delhi resulted in poor density and texture, with only about 2,500 grafts surviving out of 4,500. The user is considering holding the clinic accountable and exploring options like shaving, using hair fibers, or seeking another transplant.

The conversation discusses various theories of hair loss, including DHT sensitivity and genetic factors, with the user willing to use themselves for research due to having a hair loss gene but different hair loss patterns compared to their brothers. Specific treatments were not mentioned in the provided text.

The user experienced significant hair regrowth and darkening after 4.5 months using 1 mg Finasteride and 5% Minoxidil. Despite improvements, they are still considering a hair transplant for a better hairline.

Intradermal botulinum toxin (BTX) injections effectively treat androgenetic alopecia (AGA) by inhibiting TGF-β1 secretion from hair follicles. Further research and long-term follow-up are needed to confirm these findings.

A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).

The conversation is a satirical expression of frustration over hair loss, mentioning treatments like spironolactone, microneedling, and topical applications, with references to various hair loss products and personalities in the community.